A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
Conditions: Breast Cancer; HER2-positive Breast Cancer; ER-positive Breast Cancer Interventions: Drug: SHR6390; Drug: Anastrozole; Drug: Pyrotinib; Drug: Trastuzumab Sponsors: Ruijin Hospital; Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | Hospitals | Neoadjuvant Therapy | Research | Study